XAIR Beyond Air

Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time

GARDEN CITY, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors and tumor metastases, today announced it will report financial results for its second fiscal quarter ended September 30, 2020 on Wednesday, November 11, 2020. The Company’s management team is scheduled to host a conference call and webcast on at 4:30 pm Eastern Time the same day.

Conference Call & Webcast

Wednesday, November 11 @ 4:30 pm ET

Domestic:877-407-0784
International:201-689-8560
Passcode:13711694
Webcast:

About Beyond Air, Inc.

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit™ can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit™ for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit .

CONTACTS:

Steven Lisi, Chief Executive Officer

Beyond Air, Inc.

Maria Yonkoski, Head of Investor Relations

Beyond Air, Inc.

Corey Davis, Ph.D.

LifeSci Advisors, LLC



(212) 915-2577

EN
23/10/2020

Underlying

XAIRBeyond Air

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beyond Air

 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Result...

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit® PH actively shipping to Europe,...

June 17, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the submission of a premarket app...

June 16, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference...

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...

May 20, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections U...

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a p...

April 24, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndr...

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug ...

April 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch